drugset / Trial / NCT06529822
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.
Timeline
- Start
- 2025-03-20
- Primary completion
- 2030-01-31
- Completion
- 2034-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Synthetic long peptide personalized cancer vaccine | Vaccine | — | Intramuscular |
| Background | Hiltonol | Other / unclassified | — | Intramuscular |